Relationship Between Level of GPCR Autoantibodies and Cardiac Structure & Funtions Based on UCG and CMR

Capital Medical University

Status: Unknown

Conditions: STEMI

Study type: Observational

Funder types: Other

Identifiers

NCT05368584

BFH-autoantibodies and STEMI

Details and patient eligibility

About

This study is a prospective cohort study，we want to observe the changes of different cardiovascular antibody levels in STEMI patients undergoing emergency PCI;and combined with different cardiovascular antibody levels and various indicators, evaluate the impact of ischemia-reperfusion injury and prognosis in STEMI patients after emergency PCI.

Full description

This study mainly observed the changes of different cardiovascular antibody levels in STEMI patients undergoing emergency PCI by measuring autoantibodies; and the changes of autoantibodies in STEMI patients compared with coronary angiography-negative patients. At the same time, combined with different cardiovascular antibody levels and various indicators, the effect of ischemia-reperfusion injury and prognosis after emergency PCI in STEMI patients was evaluated. The correlation between autoantibody changes and imaging indicators in STEMI patients was evaluated by cardiac color Doppler ultrasound and CMR.

Enrollment: 1 estimated patient

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• STEMI patients meet the diagnostic criteria of "Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2015)"; ②STMEI patients undergoing emergency PCI should undergo emergency PCI within 12 hours of onset at Beijing Friendship Hospital affiliated to Capital Medical University; ③ The selected patients were able to complete the MRI and STE examinations; ④ They agreed to be enrolled in the trial and signed the informed consent.

Exclusion criteria

• Past myocardial infarction or revascularization (PCI or CABG); ②Congestive heart failure LVEF<40%; ③Atrial fibrillation; ④Renal insufficiency (GFR<30 ml/min); disease; ⑥ rheumatic immune system disease; ⑦ malignant tumor; ⑧ claustrophobia; ⑨ contraindication to CMR;